A close look at current γδ T-cell immunotherapy
Owing to their antitumor and major histocompatibility complex (MHC)-independent capacities, γδ T cells have gained popularity in adoptive T-cell immunotherapy in recent years. However, many unknowns still exist regarding γδ T cells, and few clinical data have been collected. Therefore, this review a...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-03-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1140623/full |
| _version_ | 1797854994724028416 |
|---|---|
| author | Ling Ma Ling Ma Yanmin Feng Zishan Zhou |
| author_facet | Ling Ma Ling Ma Yanmin Feng Zishan Zhou |
| author_sort | Ling Ma |
| collection | DOAJ |
| description | Owing to their antitumor and major histocompatibility complex (MHC)-independent capacities, γδ T cells have gained popularity in adoptive T-cell immunotherapy in recent years. However, many unknowns still exist regarding γδ T cells, and few clinical data have been collected. Therefore, this review aims to describe all the main features of the applications of γδ T cells and provide a systematic view of current γδ T-cell immunotherapy. Specifically, this review will focus on how γδ T cells performed in treating cancers in clinics, on the γδ T-cell clinical trials that have been conducted to date, and the role of γδ T cells in the pharmaceutical industry. |
| first_indexed | 2024-04-09T20:16:20Z |
| format | Article |
| id | doaj.art-51ca64b59b584c09a384cd97d9c84875 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-09T20:16:20Z |
| publishDate | 2023-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-51ca64b59b584c09a384cd97d9c848752023-03-31T07:20:42ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-03-011410.3389/fimmu.2023.11406231140623A close look at current γδ T-cell immunotherapyLing Ma0Ling Ma1Yanmin Feng2Zishan Zhou3Institute of Molecular Medicine, College of Future Technology, Peking University, Beijing, ChinaResearch and Development Department, Beijing Dingchengtaiyuan (DCTY) Biotech Co., Ltd., Beijing, ChinaResearch and Development Department, Beijing Dingchengtaiyuan (DCTY) Biotech Co., Ltd., Beijing, ChinaResearch and Development Department, Beijing Dingchengtaiyuan (DCTY) Biotech Co., Ltd., Beijing, ChinaOwing to their antitumor and major histocompatibility complex (MHC)-independent capacities, γδ T cells have gained popularity in adoptive T-cell immunotherapy in recent years. However, many unknowns still exist regarding γδ T cells, and few clinical data have been collected. Therefore, this review aims to describe all the main features of the applications of γδ T cells and provide a systematic view of current γδ T-cell immunotherapy. Specifically, this review will focus on how γδ T cells performed in treating cancers in clinics, on the γδ T-cell clinical trials that have been conducted to date, and the role of γδ T cells in the pharmaceutical industry.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1140623/fullγδ T cellsadoptive cell transfer (ACT)cancer immunotherapyclinical trialimmunotherapy |
| spellingShingle | Ling Ma Ling Ma Yanmin Feng Zishan Zhou A close look at current γδ T-cell immunotherapy Frontiers in Immunology γδ T cells adoptive cell transfer (ACT) cancer immunotherapy clinical trial immunotherapy |
| title | A close look at current γδ T-cell immunotherapy |
| title_full | A close look at current γδ T-cell immunotherapy |
| title_fullStr | A close look at current γδ T-cell immunotherapy |
| title_full_unstemmed | A close look at current γδ T-cell immunotherapy |
| title_short | A close look at current γδ T-cell immunotherapy |
| title_sort | close look at current γδ t cell immunotherapy |
| topic | γδ T cells adoptive cell transfer (ACT) cancer immunotherapy clinical trial immunotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1140623/full |
| work_keys_str_mv | AT lingma acloselookatcurrentgdtcellimmunotherapy AT lingma acloselookatcurrentgdtcellimmunotherapy AT yanminfeng acloselookatcurrentgdtcellimmunotherapy AT zishanzhou acloselookatcurrentgdtcellimmunotherapy AT lingma closelookatcurrentgdtcellimmunotherapy AT lingma closelookatcurrentgdtcellimmunotherapy AT yanminfeng closelookatcurrentgdtcellimmunotherapy AT zishanzhou closelookatcurrentgdtcellimmunotherapy |